Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Hudson, J. I. Articles by Jonas, J. M. Search for Related Content PubMed Citation Articles by Hudson, J. I. Articles by Jonas, J. M. Eating Disorders Antidepressants

Fluvoxamine in the Treatment of Binge-Eating Disorder: A Multicenter Placebo-Controlled, Double-Blind Trial

Objective:The purpose of this study was to assess the efficacy of fluvoxamine in the treatment of binge-eating disorder. Binge-eating disorder is a newly described eating disorder characterized by recurrent episodes of binge eating but without purging behaviors. Uncontrolled reports have suggested that serotonin selective reuptake inhibitors (SSRIs) may be effective in treating this disorder. Method:Eighty-five outpatients with a DSM-IV diagnosis of binge-eating disorder were randomly assigned to receive either fluvoxamine (N=42) or placebo (N=43) in a 9-week, parallel-group, double-blind, flexible dose (50–300 mg) study at three centers. The primary outcome measures were frequency of binge eating, expressed as log ([binges/week]+1), and Clinical Global Impression (CGI) scale ratings. Secondary measures included the level of response (based on the percentage change in frequency of binges), body mass index, and Hamilton Rating Scale for Depression score. Except for the level of response, the outcome measures were analyzed by random regression methods; the treatment-by-time interaction was the measure of treatment effect.Results:Compared with placebo, fluvoxamine was associated with a significantly greater rate of reduction in the frequency of binges, rate of reduction in CGI severity scores, rate of increase in CGI improvement scores, level of response for patients who completed the 9-week study, and rate of reduction in body mass index. There was no significant difference between placebo and fluvoxamine groups in the rate of decrease in Hamilton depression scale scores. A significantly greater proportion of patients receiving fluvoxamine than those receiving placebo discontinued treatment because of an adverse medical event. Conclusions:In this placebo-controlled trial, fluvoxamine was found to be effective according to most outcome measures in the acute treatment of binge-eating disorder. Am J Psychiatry 1998; 155: 1756-1762

This article has been cited by other articles:

				D. E. Wilfley, S. J. Crow, J. I. Hudson, J. E. Mitchell, R. I. Berkowitz, V. Blakesley, B. T. Walsh, and The Sibutramine Binge Eating Disorder Research Gro Efficacy of Sibutramine for the Treatment of Binge Eating Disorder: A Randomized Multicenter Placebo-Controlled Double-Blind Study Am J Psychiatry, January 1, 2008; 165(1): 51 - 58. [Abstract] [Full Text] [PDF]

				References PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2. [Full Text]

				A. L Tata and D. R Kockler Topiramate for Binge-Eating Disorder Associated with Obesity Ann. Pharmacother., November 1, 2006; 40(11): 1993 - 1997. [Abstract] [Full Text] [PDF]

				J. C. Appolinario, J. Bacaltchuk, R. Sichieri, A. M. Claudino, A. Godoy-Matos, C. Morgan, M. T. Zanella, and W. Coutinho A Randomized, Double-blind, Placebo-Controlled Study of Sibutramine in the Treatment of Binge-Eating Disorder Arch Gen Psychiatry, November 1, 2003; 60(11): 1109 - 1116. [Abstract] [Full Text] [PDF]

				J. C. Lumeng, K. Gannon, H. J. Cabral, D. A. Frank, and B. Zuckerman Association Between Clinically Meaningful Behavior Problems and Overweight in Children Pediatrics, November 1, 2003; 112(5): 1138 - 1145. [Abstract] [Full Text] [PDF]

				S. L. McElroy, L. M. Arnold, N. A. Shapira, P. E. Keck Jr., N. R. Rosenthal, M. R. Karim, M. Kamin, and J. I. Hudson Topiramate in the Treatment of Binge Eating Disorder Associated With Obesity: A Randomized, Placebo-Controlled Trial Am J Psychiatry, February 1, 2003; 160(2): 255 - 261. [Abstract] [Full Text] [PDF]

				T. Rinne, W. van den Brink, L. Wouters, and R. van Dyck SSRI Treatment of Borderline Personality Disorder: A Randomized, Placebo-Controlled Clinical Trial for Female Patients With Borderline Personality Disorder Am J Psychiatry, December 1, 2002; 159(12): 2048 - 2054. [Abstract] [Full Text] [PDF]

				R. I. Stein, B. E. Saelens, J. Z. Dounchis, C. M. Lewczyk, A. K. Swenson, and D. E. Wilfley Treatment of Eating Disorders in Women The Counseling Psychologist, September 1, 2001; 29(5): 695 - 732. [Abstract] [PDF]

				A. E. Becker, S. K. Grinspoon, A. Klibanski, and D. B. Herzog Eating Disorders N. Engl. J. Med., April 8, 1999; 340(14): 1092 - 1098. [Full Text] [PDF]

				Fluvoxamine: A New Treatment for Binge Eating? Journal Watch Psychiatry, February 1, 1999; 1999(201): 12 - 12. [Full Text]

				Fluvoxamine for Binge Eating Journal Watch Women's Health, January 1, 1999; 1999(101): 11 - 11. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 1998 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us